Evofem Biosciences Inc (OTCPK:EVFM)
$ 0.0092 0.0001 (1.1%) Market Cap: 923,000.00 Enterprise Value: 50.25 Mil PE Ratio: 0 PB Ratio: 0 GF Score: 0/100

Evofem Biosciences Inc to Discuss the FDA Approval of Phexxi - Call Transcript

May 26, 2020 / 12:30PM GMT
Release Date Price: $10856.2 (+16.03%)
Operator

Ladies and gentlemen, thank you for standing by, and welcome to the Evofem Biosciences Conference Call. (Operator Instructions) Please be advised that today's conference is being recorded.

I'll now turn the call over to Amy Raskopf, Head of Investor Relations for Evofem Biosciences. Please go ahead.

Amy Raskopf
Evofem Biosciences, Inc. - Head of IR

Thank you, operator. Welcome, everyone, to the Evofem Biosciences conference call to discuss the FDA approval of Evofem product Phexxi. The press release we issued on Friday highlighting this important event can be accessed in the Investors section of our website at evofem.com.

Joining me on the call today are Saundra Pelletier, Evofem's Chief Executive Officer; Russ Barrans, our Chief Commercial Officer; and Jay File, our Chief Financial Officer. Our Chief Medical Officer, Dr. Kelly Culwell, will join us for the Q&A portion of this call.

As a reminder, during today's call, we will be making certain forward-looking statements, which are made only as of today, May 26, 2020. For a more

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot